Project Grant R01HD122573
- The National Institute of Child Health and Human Development awarded a Cooperative Agreement totaling $2.752 million to the University of Washington on September 18, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award funds research examining interventions and implementation strategies to evaluate the health and development of children affected by HIV, with performance extending through August 31, 2030. The research structure comprises 34...
- The National Institute of Child Health and Human Development awarded the University of South Carolina $1,751,704 on September 16, 2025, for a clustered-randomized effectiveness study testing bundled early childhood development interventions in Liberia under the Child Health and Human Development Extramural Research program (CFDA 93.865). The study, titled the BUNDLE Study, will compare cognitive, language, socio-emotional, and motor development outcomes across 2,240 children ages 6 to 30...
- The National Institute of Child Health and Human Development awarded $1.244 million to the University of North Carolina at Chapel Hill on September 9, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct the INICIO-Guatemala Study, a randomized controlled trial testing combined nutritional and caregiver interventions on child neurodevelopment in Guatemala. The study will enroll 400 Guatemalan infants in a 2×2 factorial design to assess the...
- The National Institute of Child Health and Human Development awarded Massachusetts General Hospital $642,161 on February 6, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to advance neurodevelopmental outcome prediction in children exposed to HIV using clinical features and placental imaging. The recipient will conduct an observational cohort study to determine which clinical, placental histological, and placental stereologic features predict adverse...
- The National Institute of Child Health and Human Development, part of the Department of Health and Human Services, awarded Yale University $5,063,609 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate how antiretroviral therapy exposure during pregnancy disrupts immune development and placental function in HIV-exposed uninfected infants. The research will use immunopeptidomics, transcriptomics, and functional co-culture assays...
- The National Institute of Child Health and Human Development awarded the University of Maryland, Baltimore $2,166,907 on September 16, 2025, under the Child Health and Human Development Extramural Research Projects program (CFDA 93.865, Assistance Listing 93.HDR) to extend longitudinal follow-up of a cohort of children born to mothers with and without HIV infection as they reach school age, with focus on neurocognitive development, school readiness, and the impact of gut microbiota composition...
- The National Institute of Child Health and Human Development awarded the University of North Carolina at Chapel Hill $427,625 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct target trial emulation analyzing the impact of elective labor induction at 39 weeks on birth outcomes in resource-limited settings. The award funds a 24-month research project (performance through June 30, 2028, at Chapel Hill, North Carolina) that...
- The National Institute of Child Health and Human Development awarded the University of North Carolina at Chapel Hill $108,421 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award funds research investigating the impact of state-level fetal protection laws on prenatal care, low birthweight, and preterm birth. The research applies controlled interrupted time series models to National Center for Health Statistics natality data to...
- The National Institute of Child Health and Human Development awarded the University of North Carolina at Chapel Hill $1.284 million on September 15, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to analyze differences in unintended pregnancies across state policy contexts. The research combines data from two large national longitudinal cohorts to examine how state policy contexts and demographic characteristics drive differences in unintended...
- The National Institute of Child Health and Human Development awarded $1.691 million to Harvard T.H. Chan School of Public Health on September 15, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct clinical research on HIV treatment and prevention strategies for pregnant women in Botswana. The award funds the TSEPAMO Next Generation study, which addresses two research objectives: evaluating whether two-drug antiretroviral treatment using...
The National Institute of Child Health and Human Development awarded the University of North Carolina at Chapel Hill $797,615 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to optimize the SAFE Families intervention, a family-centered program designed to improve health and developmental outcomes for children who are HIV-exposed and uninfected. The award funds a randomized factorial trial enrolling 384 mothers living with HIV during pregnancy and following them and their infants through 12 months postpartum. All participants receive core individual counseling at key timepoints and are randomized to receive up to four additional components: counseling for home supporters such as family members or close friends, tailored counseling based on maternal viral load results, facilitated digital support groups, and text messaging for mothers and home supporters. The study uses the Multiphase Optimization Strategy framework to determine which intervention components improve infant neurodevelopment at 12 months (primary outcome), as well as exclusive breastfeeding and maternal antiretroviral therapy adherence. Data collection occurs at baseline during pregnancy and at follow-up assessments at 6 weeks, 3 months, 5.5 months, and 12 months postpartum. The study also collects data from 384 home supporters at baseline and 5.5 months. Performance takes place in Chapel Hill, North Carolina. The period of performance runs from September 1, 2026, through May 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $797.6k | 8/25/26 |